Brief: Haemato Pharm GmbH Received Approval For Antigen Rapid Test For Self-Testing By Laypersons
23/03/2021 14:55
March 23 (Reuters) - HAEMATO AG HAEk.DE :
* HAEMATO PHARM GMBH AS A SUBSIDIARY OF HAEMATO AG RECEIVES
A
SPECIAL APPROVAL
* HAEMATO PHARM GMBH RECEIVED A SPECIAL FROM FEDERAL
INSTITUTE FOR
DRUGS AND MEDICAL DEVICES ( BFARM ) FOR ANTIGEN RAPID TEST FOR
SELF-TESTING BY LAYPERSONS ON 23 MARCH
* EXACT NAME OF MEDICAL DEVICE IS: "WONDFO 2019-NCOV ANTIGEN
TEST
(LATERAL-FLOW-METHODE) SELBSTTEST"
* WILL BE ABLE TO COST-EFFECTIVELY PROVIDE UP TO 200 MILLION
OF
THESE HIGH-QUALITY COVID-19 LAY TESTS TO PHARMACISTS,
WHOLESALERS AND PUBLIC INSTITUTIONS IN COMING MONTHS
* FIRST DELIVERIES ARE SCHEDULED FOR AS EARLY AS END OF
MARCH 2021
Source text for Eikon: ID:nEQ9HtJVNa
Further company coverage: HAEk.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Haemato AG
See all newsBrief: HAEMATO Raises FY EBIT Guidance to EUR 10-12 Million
Brief: Haemato Says Terminates Cooperation With Korean Manufacturer Huons Biopharma; To Discontinue Project For A Proprietary Botulinum Toxin
Brief: Haemato Q1 EBITDA At EUR 2.3 Mln
Brief: Haemato To Propose Dividend Of EUR 1.10 Per Share
Brief: Haemato Preliminary Consolidated FY EBIT Up At EUR 11.2 Mln